Table 2– Model inputs

	Base case	Low	High	[Ref.]
Median OS months
No selection^#	5.6	4.6	7.0	[8]
Clinical selection
Positive^¶	9.4	5.5	12.7	[8]
Negative⁺	8.0	5.1	10.4	[8]
EGFR-based selection
Positive^§	14.4	8.0	20.6	[8]
Negative^ƒ	8.0	5.1	10.4	[8]
Median PFS months
No selection^#	2.4	2.3	2.6	[8]
Clinical selection
Positive^¶	2.9	2.5	3.8	[8]
Negative⁺	2.8	2.2	4.2	[8]
EGFR-based selection
Positive^ƒ	8.4	3.0	15.3	[8]
Negative^##	2.8	2.2	4.2	[20]
Health state utilities				[23, 24]
Stable disease on oral therapy	0.670	0.27	0.80
Stable disease on i.v. therapy	0.653	0.26	0.78
Progressive disease	0.473	0.19	0.56
Death	0
*Prevalence of EGFR* mutation**	0.08	0.01	0.15	[8]
Cost of medical services and drugs €
Erlotinib 30-day supply 150 mg	2174.7
Mean duration of erlotinib treatment months	2.5	0.1	26.0
Docetaxel per mg	10.7
Mean number of docetaxel cycles	3.7±1.9
Cost of hospitalisation for docetaxel administration	368
Frequency of hospitalisation for adverse events	0.44±0.84			[25]
G-CSF injection per cycle	557.4	1627	3021
Erythropoietin per cycle	199.1	91	400
Palliative care after progression per month	2324
EGFR test	130

OS: overall survival; EGFR: epidermal growth factor receptor; PFS: progression-free survival; G-CSF: granulocyte colony-stimulating factor. ^#: n=522; ^¶: n=114; ⁺: n=408; ^§: n=44; ^ƒ: n=478; ^##: n=75.